SCHEMBL3129593

SCHEMBL3129593

NC(=O)CCc1ccnc(CO)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 1/20 0.42
NR3C2 P08235 11/20 0.41
GRM2 Q14416 1/20 0.40
AURKA O14965 1/20 0.39
RECQL P46063 1/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
GABRA4 P48169 1/20 0.38
GABRE P78334 1/20 0.38
GABRA6 Q16445 1/20 0.38
GABRG1 Q8N1C3 1/20 0.38
GABRG3 Q99928 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23015824 0.85 CYP1A2 (0.50) CAPN1NR3C2AURKAGABRPGABRD
SCHEMBL5361827 0.81 CAPN1 (0.43) CAPN1NR3C2AURKAGABRPGABRD
SCHEMBL1388918 0.80 GRM2 (0.46) NR3C2GRM2TSHR
SCHEMBL3129466 0.79 CYP4F2 (0.42) CAPN1NR3C2AURKAGABRPGABRD
SCHEMBL3398155 0.79 FFAR1 (0.48) CAPN1NR3C2AURKALMNAALDH1A1
SCHEMBL3121398 0.79 CAPN1 (0.42) CAPN1NR3C2AURKAGABRPGABRD
SCHEMBL23015679 0.78 NOS3 (0.49) CAPN1NR3C2GABRPGABRDGABRA1
SCHEMBL3129887 0.77 ALDH1A1 (0.41) CAPN1NR3C2AURKAGABRPGABRD
SCHEMBL3123399 0.77 CAPN1 (0.40) CAPN1NR3C2AURKAGABRPGABRD
SCHEMBL16318580 0.76 CYP4F2 (0.56) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010036632-A1 AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-01 WO disclosed